Treatment of metastatic glucagonoma to the liver: Case report and literature review

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 4, 1999, Pages 308-312

  Casadei, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Glucagonoma; Hepatic; Hepatic arterial chemoembolization; Metastases; Octreotide

Indexed keywords

DOXORUBICIN; GELATIN SPONGE; GLUCAGON; OCTREOTIDE; STREPTOZOCIN;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; GLUCAGON BLOOD LEVEL; GLUCAGONOMA; HUMAN; LIVER METASTASIS; MALE; MEDICAL LITERATURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; GLUCAGONOMA; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATIC NEOPLASMS;

EID: 0033026591     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Becker SW, Kahn D, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syphilotol 1942;45:1068-80.
2. Me Gavran M, Unger R, Recant L. A glucagon-secreting alpha cell carcinoma of the pancreas. N Engl J Med 1966;274:1408-13.
3. Mallison CN, Bloom SR, Warin AP. A glucagonoma syndrome. Lancet 1974;1:1-3.
4. Guillausseau PJ, Guillausseau C, Villet R, Kaloustian E, Valleur P, Hautefeuille P, et al. Les glucagonomas. Aspects cliniques, biologiques, anatomopathologiques et therapeutiques. Gastroenterol Clin Biol, 1982;6:1029-41.
5. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine 1996;75:53-63.
6. Leichter SB. Clinical and metabolic aspects of glucagonoma. Medicine, 1980;59:100-13.
7. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis and treatment. Endocrinol Rev 1981;2:347-61.
8. Penchet A, Olivier A, Passa P, Orsoni JL, Charleux H. Le syndrome de glucagonome. Revue de la littérature. A propos d'un cas. JChir 1986:123:157-63.
9. Santangelo WC, Unger RH, Orci L, Dueno MI, Popma JJ, Krejs GJ. Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration. Pancreas 1986; 1:464-9.
10. Fujita J, Seino Y, Ishida H, Taminato T, Matsukura S, Horio T, et al. A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome. Cancer 1986;57:860-5.
11. Altimari AF, Bhoopalam N, O'Dorsio T, Lange CL, Sandberg L, Prinz AR. Use of a Somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery 1986:100:989-96.
12. Van der Loos TLJM, Lambrecht ER, Lambers JCCA. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine. J Am Acad Dermatol 1987;2:468-72.
13. Jeanmougin M, Civatte J, Bonvalet D, Passa P, Verola O, Zylberait D. Glucagonome métastatique. Rémission complète par la dacarbazine. Ann Dermatol Venereol 1988;! 15:833-8.
14. Sheehan-Dare RA, Simmons AV, Cotterill JA, Janke PJ. Hepatic tumours with hyperglucagonemia. Cancer 1988;62:912-4.
15. Cavallo-Perin P, De Paoli M, Guiso G, Sapino A, Papotti M, Coda R, et al. A combined glucagonoma and vipoma syndrome. First pathologic and clinical report. Cancer 1988;62:2576-9.
16. Picard C, Mazer JM, Bilet S, Villette B, Penchet A, Toublanc M, et al. Syndrome du glucagonome. Ann Dermatol Venereol 1988:115:1142-5.
17. Reyes-Govea J, Holm A, Aldrete JS. Response of glucagonomas to surgical excision and chemotherapy. Report of two cases and review of the literature. Am Surg 1989:55:523-7.
18. Biliotti GC, Vestrini G, Tonelli P, Vallecchi C. La sindrome da glucagonoma. Rilievi clinico-terapeutici relativi ad una osservazione personale e revisione della letteratura. Min Chir 1989:44:163-72.
19. Rosenbaum A, Flourie B, Chagnon S, Blery M, Modigliani R. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. Digestion 1989:42:116-20.
20. Hercot O, Legmann P, Humbert M, Sibert A, Somveille E, Picard C, et al. Diagnostic du glucagonome. J Radiol 1989:4:309-16.
21. Moattari AR, Cho K, Vinik AI. Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses. Surgery 1990:108:581-7.
22. Edney J, Hofmann S, Thompson JS, Kessinger A. Glucagonoma syndrome is an underdiagnosed clinical entity. Am J Surg 1990;160:625-9.
23. Freimann J, Pazdur R. Hepatic arterial embolization for treatment of glucagonomas: antineoplastic and palliative benefits. Am J ClinOncol 1990:13:271-5.
24. Jones DV, Samaan NA, Sellin RV, Ajani JA. Metastatic glucagonoma: clinical response to a combination of 5-Fluorouracil and α-Interferon. Am J Med 1992:93:348-9.
25. Shepherd ME, Raimer SS, Tyring SK, Smith EB. Treatment of necrolytic migratory erythema in glucagonoma syndrome. J Am Acad Dermatol 1991:25:925-8.
26. Arnaud A, Fetissof F, Lorette G, Reigner J, Bertrand G, Lecomte P. Le syndrome du glucagonome: trois nouveaux cas. Rev Med Int 1992;2:103-8.
27. Klein S, Jahoor F, Baba H, Townsend CM, Shepherd M, Wolfe RR. In vivo assessment of the metabolic alterations in glucagonoma syndrome. Metabolism 1992:41:1171-5.
28. Jockenhövel F, Lederbogen S, Olbricht T, Schmidt-Gayk, Krenning EP, Lamberts SWJ, et al. The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumour growth. Clin Invest 1994;72:127-33.
29. Manes G, Pellegrini A, Riccardi F, Uomo G. Rare presentation of endocrine pancreatic tumour: a case of glucagonoma without necrolytic migratory erythema? Ital J Gastroenterol 1995:27:248-9.
30. Bewley AP, Ross JS, Bunker CB, Staughton RCD. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema. Br J Dermatol 1996:134:1101-4.
31. Ferrari A, Gavinelli M, Dominioni L, Carcano G, Dionigi R. Sonographic features of liver metastases from pancreatic glucagonoma and acinar cell carcinoma. Surg Endosc 1996:10:762-4.
32. Anthuber M, Jauch KW, Briegel J, Groh J, Schildberg FW. Results of liver transplantation for gastroenteropancreatic tumour métastases. World J Surg 1996;20:73-6.
33. Modlin IM, Lewis JJ, Amman H, Bilchik AJ, Kuman RR. Management of unresectable malignant endocrine tumours of the pancreas. Surg Gynecol Obstet 1993:176:507-18.
34. Perry LJ, Stuart K, Stokes KS, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumours. Surgery 1994; 116:1111-7.